Non-Muscle-Invasive Bladder Cancer (NMIBC)
Conditions
Brief summary
This study aims to evaluate the efficacy and safety of intravenous administration of vedacitinib combined with intravesical instillation of mitomycin in treating patients with high-risk NMIBC with HER2 expression. The goal is to provide a new treatment option for NMIBC patients, reduce the risk of tumor recurrence, decrease the proportion of radical bladder surgery, and improve the quality of life of patients.
Interventions
DRUGDisitamab Vedotin
Disitamab Vedotin injection: 2.0 mg/kg, every two weeks, treatment lasts for 8 to 12 cycles
Mitomycin bladder intravesical instillation: 40mg per dose. Instill immediately after surgery, then once a week thereafter. The induction chemotherapy instillation lasts for 8 times. Subsequently, it is instilled once a month for a total of 10 months for maintenance chemotherapy.
Sponsors
Shanxi Province Cancer Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Voluntary participation, signing a written informed consent form; * The age on the date of signing the informed consent form should be no less than 18 years old, regardless of gender; * The subjects have completed the standard TURBT procedure before signing the informed consent form, and no obvious residual tumor lesions were found in the surgical field; * The postoperative pathology clearly diagnosed as non-muscle-invasive bladder cancer, and the main tissue component was more than 50% urothelial carcinoma (transitional cell carcinoma); * The subjects were classified into the intermediate-risk or high-risk group according to the risk classification for NMIBC; * Tumor tissue samples for TURBT must be provided, along with the required relevant pathological reports. Fresh surgical tissues or pathological slides can be sent for examination as well; * The patients were intolerant to BCG or did not accept the BCG infusion treatment plan; * Before treatment, HER2 detection was conducted on the resection specimens in the laboratory: The IHC results confirmed HER2 expression (defined as: IHC 1+, 2+ or 3+); * Clinical non-metastatic bladder cancer (N0, M0) was determined by abdominal computed tomography (CT).
Exclusion criteria
* History of muscle-invasive bladder cancer or metastatic bladder cancer before treatment;History of muscle-invasive bladder cancer or metastatic bladder cancer before treatment; * Imaging results within 3 months before treatment indicated lymph node or other site/organ metastasis; * Imaging results within 3 months before treatment indicated the presence of other urinary system tumors; * Received other systemic anti-cancer treatments within 3 weeks before treatment, including chemotherapy, biological therapy, immunotherapy, targeted therapy, endocrine therapy, and/or investigational drug therapy; * Received bladder radiotherapy for urothelial carcinoma before treatment; * Known to have anaphylaxis or delayed allergic reaction to certain components of vedacitinib or similar drugs; * Within the 3 days prior to the first infusion, the following conditions had not yet been alleviated to CTCAE grade 1:Uncontrolled acute or chronic infections, such as pneumonia, biliary tract infections;Hepatitis B and Hepatitis C infections; dyspnea;Acute or chronic kidney injury; nephrotic syndrome; bladder perforation; urinary tract obstruction; * NYHA rating of 3 or 4; * Symptoms and signs related to cardiovascular diseases: including myocardial infarction, congestive heart failure, arrhythmia, etc.; * Known cerebrovascular accidents; * History of autoimmune diseases (such as inflammatory bowel disease, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, hemolytic anemia, rheumatoid arthritis, etc.); * Known positive HIV serology, Hepatitis C infection and/or Hepatitis B (HepBsAg or core antibody positive and responding after antiviral treatment for Hepatitis B, except for these patients: these patients are allowed to participate in this study; Note: Patients with negative HepBsAg at screening)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 1-year disease-free survival rate(1-year DFS rate) | At 12 months after the first study treatment. | defined as the time from study treatment initiation to disease recurrence (confirmed by cystoscopic biopsy or imaging), disease progression (muscle invasion or distant metastasis), or death from any cause, estimated by the Kaplan-Meier method. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease-free survival | From drug combination to the first documented recurrence, disease progression, death from any cause, or last follow-up, assessed up to 12 months. | Disease-free survival is defined as the time from the date of first study treatment to the first documented recurrence, disease progression, death from any cause, or last disease assessment, whichever occurred first. |
| Overall Survival（OS） | From the date of first study treatment to the date of death from any cause or last known follow-up, whichever occurred first, assessed up to 12 months. | Overall survival is defined as the time from the date of first study treatment to death from any cause. Participants who are alive at the last follow-up will be censored at the date of last known follow-up. |
| Incidence and Severity of Treatment-emergent Adverse Events | From the date of first study treatment until 30 days after the last dose of study treatment, assessed up to 12 months. | Treatment-emergent adverse events are defined as adverse events that occur or worsen after initiation of study treatment. Adverse events will be recorded and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. |
Countries
China
Contacts
CONTACTXuebing Han
Outcome results
None listed